Novel compounds to treat cardiovascular disease related to dyslipidemia.
Dezima Pharma develops novel compounds to treat cardiovascular disease related to dyslipidemia. Dezima's TULIP study was published in The Lancet in June 2015. On September, 16, 2015, Amgen agreed to acquire all outstanding shares of Dezima for up to US$1.55 billion.
Human Health
NL
Naarden
The Netherlands
Industry
Biotech
Status
Realised
Location
The Netherlands